US2006252688A1PendingUtilityA1

Therapeutic uses of BPI protein products in BPI-deficient humans

57
Assignee: LEVY OFERPriority: Apr 1, 1999Filed: May 1, 2006Published: Nov 9, 2006
Est. expiryApr 1, 2019(expired)· nominal 20-yr term from priority
Inventors:Ofer Levy
A61K 38/1751
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

New therapeutic uses for BPI protein products that involve treatment of subjects with a BPI deficiency condition, including selective BPI deficiency, and newborns, including BPI-deficient newborns.

Claims

exact text as granted — not AI-modified
1 . A method of treating a subject with a BPI deficiency condition comprising administering to said subject an amount of BPI protein product effective to alleviate the BPI deficiency.  
     
     
         2 . The method of  claim 1  wherein the subject is an adult.  
     
     
         3 . The method of  claim 1  wherein the condition is a selective BPI deficiency.  
     
     
         4 . The method of  claim 1  wherein the subject is a newborn.  
     
     
         5 . The method of  claim 4  wherein the newborn is a premature newborn.  
     
     
         6 . The method of  claim 1  wherein the BPI protein product is rBPI 21 .  
     
     
         7 . The method of  claim 1  wherein the BPI protein product is an N-terminal fragment of BPI having a molecular weight approximately between about 20 to 25 kd.  
     
     
         8 . The method of  claim 1  wherein the BPI protein product is rBPI(10-193)ala 132 .  
     
     
         9 . The method of  claim 1  wherein the BPI protein product is rBPI 50 .

Join the waitlist — get patent alerts

Track US2006252688A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.